The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
In Vivo Metabolism of ApoB, ApoA-I, and VLDL Triglycerides in a Form of Hypobetalipoproteinemia Not Linked to the ApoB Gene
Abstract
Abstract —Familial hypobetalipoproteinemia (FHBL) is an autosomal codominant disorder that may result from different mutations in the apolipoprotein B (apoB) gene or chromosome 2. However, linkage of FHBL to the apoB gene was ruled out in 2 kindreds reported to date, and the genetic and metabolic bases for FHBL remain unknown. One of the reported kindreds is our 40-member F kindred, in which we found linkage of FHBL to a novel susceptibility region on chromosome 3p21.1-2. In addition to having low apoB levels, some, but not all, of the affected subjects in the F kindred also had low levels of high density lipoprotein (HDL) cholesterol and apoA-I. Our aim was to define the metabolic bases of the disorder in the F kindred. Therefore, we studied the in vivo kinetics of apoB and apoA-I and very low density lipoprotein (VLDL) triglycerides in 4 affected subjects and 5 normolipidemic relatives. Deuterated leucine and deuterated glycerol were used to label the apolipoproteins and triglycerides, respectively. Compartmental modeling was used to obtain the kinetic parameters. Affected subjects had (1) normal fractional catabolic rates (FCRs) for VLDL apoB, (2) increased FCRs for low density lipoprotein (LDL) apoB (0.050±0.009 versus 0.030±0.006 pools per hour for normal subjects, P =0.005), and (3) decreased production rates of VLDL apoB (11.4±1.7 versus 25.6±4.9 mg · kg −1 · d −1 , P =0.003), LDL apoB (7.8±1.3 versus 12.7±3.7 mg · kg −1 · d −1 , P =0.04), and VLDL triglycerides (8.2±4.5 versus 19.6±10.8 58 μmol · kg −1 · h −1 , P =0.09). These data differ from those obtained in previously studied FHBL heterozygotes bearing apoB-2 and apoB-9, 2 very short truncations of apoB. Low HDL cholesterol and apoA-I levels were caused by higher apoA-I FCRs (0.035±0.005 versus 0.018±0.005 pools per hour in controls, P <0.01) without significant decrease in apoA-I production rates (18.7±2.7 versus 22.8±5.6 mg · kg −1 · d −1 ). In conclusion, decreased secretion of apoB-containing lipoproteins and hypercatabolism of LDL account for low apoB and cholesterol levels in this novel form of FHBL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The affected family members presented with lower VLDL apoB production rates, and increased IDL and LDL apoB FCRs compared with unaffected family controls,16 with a clear gene dose effect.1”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [16]
In the citing paper
“Our results are in line with an earlier published apoB kinetic study in a family with familial hypobetalipoproteinemia,16 which was later reclassified as familial combined hypolipidemia caused by ANGPTL3 LOF variants.1”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [16]
Citations
Cites
Brinton, E. A., Eisenberg, S., & Breslow, J. L. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.5.707 · Cited by 265
Research works printed but not linked: 39
- Kane JP Havel RJ Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR Beaudet AL Sly WS Valle D eds. The Metabolic Bases of Inherited Disease. 7th ed. New York NY: McGraw-Hill Book Co; 1995:1853–1885.
- 10.1073/pnas.77.1.604 · DOI
- 10.1126/science.1439810 · DOI
- 10.1016/0016-5085(87)90133-8 · DOI
- 10.1016/S0022-2275(20)32131-3 · DOI
- 10.1161/atvb.18.11.1745 · DOI
- 10.1146/annurev.nu.15.070195.000323 · DOI
- 10.1016/S0022-2275(20)39976-4 · DOI
- 10.1016/S0022-2275(20)37582-9 · DOI
- 10.1172/JCI115799 · DOI
- 10.1016/S0022-2275(20)41419-1 · DOI
- 10.1161/01.ATV.15.1.71 · DOI
- 10.1111/j.1365-2796.1991.tb00304.x · DOI · Paper page
- 10.1002/(SICI)1096-8628(19980226)76:1<79::AID-AJMG15>3.0.CO;2-M · DOI
- Yuan B Neuman R Duan SH Weber JL Kwok PY Saccone NL WU JS Liu KY Schonfeld G. Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1–22. Am J Hum Genet. In press.
- 1988, Pharm Biocommun, 4, 4
- 1983, Methods Enzymol, 128, 417
- 10.1016/S0022-2275(20)41961-3 · DOI
- 10.1016/S0021-9258(19)52451-6 · DOI
- 10.1016/S0021-9673(00)84078-9 · DOI
- 10.1016/S0022-2275(20)34455-2 · DOI
- 10.1016/S0022-2275(20)41970-4 · DOI
- 10.1016/S0022-2275(20)32435-4 · DOI
- 1999, Am J Physiol, 276, E278
- 10.1161/atvb.19.11.2714 · DOI
- 10.1172/JCI109421 · DOI
- 10.1016/S0076-6879(96)63009-2 · DOI
- 10.1111/j.1365-2362.1980.tb02076.x · DOI
- 10.1161/atvb.17.5.881 · DOI
- 10.1097/00041433-199510000-00006 · DOI
- 10.1161/atvb.16.10.1229 · DOI
- 10.1016/S0022-2275(20)42269-2 · DOI
- 10.1073/pnas.93.21.11991 · DOI
- 10.1016/S0021-9258(19)49411-8 · DOI
- 1976, Science, 191, 151
- 10.1161/circ.94.1.1 · DOI
- 10.1172/JCI115028 · DOI
- 10.1161/atv91.13.9.8364014 · DOI
- 10.1172/JCI5286 · DOI
Cited by
Sorted by citations
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Self-citationHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Minicocci, I., Montali, A., Robciuc, M. R., Quagliarini, F., Censi, V., Labbadia, G., Gabiati, C., Pigna, G., Sepe, M. L., Pannozzo, F., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1298 · Cited by 168
Patterson, B. W., Mittendorfer, B., Elias, N., Satyanarayana, R., & Klein, S. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30164-4 · Cited by 118
Self-citationReeskamp, L. F., Millar, J. S., Wu, L., Jansen, H., van Harskamp, D., Schierbeek, H., Gipe, D. A., Rader, D. J., Dallinga-Thie, G. M., Hovingh, G. K., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315204 · Cited by 109
Metadata
- Authors
- Elias, N., Patterson, B. W., & Schonfeld, G.
- Affiliations
- From the Division of Atherosclerosis, Lipid Research, and Nutrition, and the Division of Gastroenterology (B.W.P.), Department of Internal Medicine, Washington University School of Medicine, St Louis, Mo.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2000-05
- Volume
- 20
- Issue
- 5
- Pages
- 1309-1315
- ISSN
- 1079-5642
- 1524-4636
- Cited by
- 32
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review